OR WAIT 15 SECS
Optimer Pharmaceuticals, Inc. announces that data highlighting the burden of Clostridium difficile infection using national health insurance claims and survey databases will be presented on April 2, 2011 at the 21st annual scientific meeting of the Society for Healthcare Epidemiology of America (SHEA).
Erik R. Dubberke, MD, MSPH, of Washington University School of Medicine in St. Louis, will present the poster, "Rates of Recurrence and Mortality Among Patients with a Diagnosis of Clostridium Difficile Infection in the United States: An Analysis Using National Health Insurance Claims and Survey Databases on Saturday, April 2, 2011 from 1 p.m. to 2:15 p.m. CT in the Trinity Ballroom at the Hilton Anatole Hotel in Dallas.
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development.